• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Hepatic Medicine : Evidence and Research >Morphological and functional MDCT: problem-solving tool and surrogate biomarker for hepatic disease clinical care and drug discovery in the era of personalized medicine
【2h】

Morphological and functional MDCT: problem-solving tool and surrogate biomarker for hepatic disease clinical care and drug discovery in the era of personalized medicine

机译：形态学和功能性MDCT：个性化医学时代用于肝病临床护理和药物发现的问题解决工具和替代生物标记

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This article explains the significant role of morphological and functional multidetector computer tomography (MDCT) in combination with imaging postprocessing algorithms served as a problem-solving tool and noninvasive surrogate biomarker to effectively improve hepatic diseases characterization, detection, tumor staging and prognosis, therapy response assessment, and novel drug discovery programs, partial liver resection and transplantation, and MDCT-guided interventions in the era of personalized medicine. State-of-the-art MDCT depicts and quantifies hepatic disease over conventional CT for not only depicting lesion location, size, and extent but also detecting changes in tumor biologic behavior caused by therapy or tumor progression before morphologic changes. Color-encoded parameter display provides important functional information on blood flow, permeability, leakage space, and blood volume. Together with other relevant biomarkers and genomics, the imaging modality is being developed and validated as a biomarker to early response to novel, targeted anti-VEGF(R)/PDGFR or antivascular/angiogenesis agents as its parameters correlate with immunohistochemical surrogates of tumor angiogenesis and molecular features of malignancies. MDCT holds incremental value to World Health Organization response criteria and Response Evaluation Criteria in Solid Tumors in liver disease management. MDCT volumetric measurement of future remnant liver is the most important factor influencing the outcome of patients who underwent partial liver resection and transplantation. MDCT-guided interventional methods deliver personalized therapies locally in the human body. MDCT will hold more scientific impact when it is fused with other imaging probes to yield comprehensive information regarding changes in liver disease at different levels (anatomic, metabolic, molecular, histologic, and other levels).
机译：本文解释了形态学和功能多探测器计算机断层扫描（MDCT）与成像后处理算法相结合的重要作用，该算法用作解决问题的工具和无创替代生物标志物，可有效改善肝病的特征，检测，肿瘤分期和预后，治疗反应评估，以及新颖的药物发现计划，部分肝切除和移植以及MDCT指导的个性化医学时代的干预措施。与传统的CT相比，最先进的MDCT可以描绘和量化肝脏疾病，不仅可以描绘病变的位置，大小和程度，还可以在形态学改变之前检测由治疗或肿瘤进展引起的肿瘤生物学行为的改变。颜色编码的参数显示提供有关血流量，渗透性，泄漏空间和血容量的重要功能信息。与其他相关的生物标志物和基因组学一起，正在开发成像方式，并将其作为对新型靶向VEGF / PDGFR或抗血管/血管生成剂的早期反应的生物标志物进行验证，因为其参数与肿瘤血管生成和免疫组织化学指标相关。恶性肿瘤的分子特征。 MDCT对世界卫生组织肝脏疾病管理中实体瘤的响应标准和响应评估标准具有递增的价值。未来残留肝脏的MDCT体积测量是影响部分肝切除和移植患者预后的最重要因素。 MDCT指导的介入方法在人体局部提供个性化疗法。当将MDCT与其他成像探头融合以产生有关不同水平（解剖，代谢，分子，组织学和其他水平）肝病变化的全面信息时，MDCT将具有更科学的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号